Recent Progress in the Diagnosis and Precise Nanocarrier-Mediated Therapy of Inflammatory Bowel Disease

References

• Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28(1):573–621. doi:10.1146/annurev-immunol-030409-101225
   PubMed Web of Science ®Google Scholar
• Alhouayek M, Muccioli GG. The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. Trends Mol Med. 2012;28:615–625. doi:10.1016/j.molmed.2012.07.009
   Google Scholar
• Moran CJ, Huang H, Rivas M, et al. Genetic variants in cellular transport do not affect mesalamine response in ulcerative colitis. PLoS One. 2018;13(3):e0192806. doi:10.1371/journal.pone.0192806
   PubMed Web of Science ®Google Scholar
• Taylor KM, Irving PM. Optimization of conventional therapy in patients with IBD. Nat Rev Gastroenterol Hepatol. 2011;8(11):646. doi:10.1038/nrgastro.2011.172
   PubMed Web of Science ®Google Scholar
• Bryant RV, Brain O, Travis SPL. Conventional drug therapy for inflammatory bowel disease. Scand J Gastroenterol. 2015;50(1)::90–112. doi:10.3109/00365521.2014.968864
   PubMed Web of Science ®Google Scholar
• Cario E. P-glycoprotein multidrug transporter in inflammatory bowel diseases: more questions than answers. World J Gastroenterol. 2017;23:1513–1520.
   PubMed Web of Science ®Google Scholar
• Walker G, Ahmad T. Drug toxicity: personalising IBD therapeutics – the use of genetic biomarkers to reduce drug toxicity. In: Sheng Ding N, De Cruz P, editors. Biomarkers in Inflammatory Bowel Diseases. Cham: Springer International Publishing; 2019:257–269.
   Google Scholar
• Nance E, Zhang C, Shih T-Y, et al. Brain-penetrating nanoparticles improve paclitaxel efficacy in malignant glioma following local administration. ACS Nano. 2014;8:10655–10664.
   PubMed Web of Science ®Google Scholar
• Lamprecht A. Selective nanoparticle adhesion can enhance colitis therapy. Nat Rev Gastroenterol Hepatol. 2010;7:311.
   PubMed Web of Science ®Google Scholar
• Hua S, Marks E, Schneider JJ, et al. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. Nanomedicine. 2015;11(5):1117–1132. doi:10.1016/j.nano.2015.02.018
   PubMed Web of Science ®Google Scholar
• Mittal R, Patel AP, Jhaveri VM, et al. Recent advancements in nanoparticle based drug delivery for gastrointestinal disorders. Expert Opin Drug Deliv. 2018;15(3):301–318. doi:10.1080/17425247.2018.1420055
   PubMed Web of Science ®Google Scholar
• Sahoo SK, Misra R, Parveen S. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. In: Nanomedicine in Cancer. Pan Stanford; 2017:73–124.
   Google Scholar
• Guada M, Beloqui A, Alhouayek M, et al. Cyclosporine A-loaded lipid nanoparticles in inflammatory bowel disease. Int J Pharm. 2016;503(1–2):196–198. doi:10.1016/j.ijpharm.2016.03.012
   PubMedGoogle Scholar
• Mir M, Ahmed N, Rehman AU. Recent applications of PLGA based nanostructures in drug delivery. Colloids Surf B Biointerfaces. 2017;159:217–231. doi:10.1016/j.colsurfb.2017.07.038
   PubMed Web of Science ®Google Scholar
• Hossain MA, Yamashita M, Vong LB, et al. Silica-installed redox nanoparticles for novel oral nanotherapeutics – improvement in intestinal delivery with anti-inflammatory effects. J Drug Target. 2014;22(7):638–647. doi:10.3109/1061186X.2014.928716
   PubMed Web of Science ®Google Scholar
• Yang B, Jiang J, Jiang L, et al. Chitosan mediated solid lipid nanoparticles for enhanced liver delivery of zedoary turmeric oil in vivo. Int J Biol Macromol. 2020;149:108–115. doi:10.1016/j.ijbiomac.2020.01.222
   PubMed Web of Science ®Google Scholar
• Zhai J, Mantaj J, Vllasaliu D. Ascorbyl palmitate hydrogel for local, intestinal delivery of macromolecules. Pharmaceutics. 2018;10(4):188. doi:10.3390/pharmaceutics10040188
   PubMed Web of Science ®Google Scholar
• Tong T, Qi Y, Bussiere LD, et al. Transport of artificial virus-like nanocarriers through intestinal monolayers via microfold cells. Nanoscale. 2020;12(30):16339–16347. doi:10.1039/D0NR03680C
   PubMed Web of Science ®Google Scholar
• Argyo C, Weiss V, Bräuchle C, et al. ChemInform abstract: multifunctional mesoporous silica nanoparticles as a universal platform for drug delivery. Cheminform. 2014;45(11):435–451. doi:10.1002/chin.201411272
   Google Scholar
• Youshia J, Lamprecht A. Size-dependent nanoparticulate drug delivery in inflammatory bowel diseases. Expert Opin Drug Deliv. 2016;13(2):281–294. doi:10.1517/17425247.2016.1114604
   PubMed Web of Science ®Google Scholar
• Yong MJ, Mantaj J, Cheng Y, et al. Delivery of nanoparticles across the intestinal epithelium via the transferrin transport pathway. Pharmaceutics. 2019;11(7):298. doi:10.3390/pharmaceutics11070298
   PubMed Web of Science ®Google Scholar
• Bharti C, Nagaich U, Pal AK, et al. Mesoporous silica nanoparticles in target drug delivery system: a review. Int J Pharm Investig. 2015;5:124–133.
   PubMed Web of Science ®Google Scholar
• Beloqui A, Coco R, Memvanga PB, et al. pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease. Int J Pharm. 2014;473:203–212.
   PubMed Web of Science ®Google Scholar
• Yao Y, Zhang H, Wang Z, et al. Reactive oxygen species (ROS)-responsive biomaterials mediate tissue microenvironments and tissue regeneration. J Mater Chem B. 2019;7(33):5019–5037. doi:10.1039/C9TB00847K
   PubMed Web of Science ®Google Scholar
• Xu W, Ling P, Zhang T. Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs Journal of Drug Delivery. 2013;2013:15.
   Google Scholar
• Felber AE, Dufresne M-H, Leroux J-C. pH-sensitive vesicles, polymeric micelles, and nanospheres prepared with polycarboxylates. Adv Drug Del Rev. 2012;64:979–992. doi:10.1016/j.addr.2011.09.006
   PubMed Web of Science ®Google Scholar
• Sood A, Panchagnula R. Peroral route: an opportunity for protein and peptide drug delivery. Chem Rev. 2001;101(11):3275–3304. doi:10.1021/cr000700m
   PubMed Web of Science ®Google Scholar
• Bertoni S, Machness A, Tiboni M, et al. Reactive oxygen species responsive nanoplatforms as smart drug delivery systems for gastrointestinal tract targeting. Biopolymers. 2020;111(1):e23336. doi:10.1002/bip.23336
   PubMed Web of Science ®Google Scholar
• Sogias IA, Williams AC, Khutoryanskiy VV. Why is chitosan mucoadhesive? Biomacromolecules. 2008;9(7):1837–1842. doi:10.1021/bm800276d
   PubMed Web of Science ®Google Scholar
• Cook MT, Tzortzis G, Charalampopoulos D, et al. Microencapsulation of probiotics for gastrointestinal delivery. J Control Release. 2012;162(1):56–67. doi:10.1016/j.jconrel.2012.06.003
   PubMed Web of Science ®Google Scholar
• Khutoryanskiy VV. Advances in mucoadhesion and mucoadhesive polymers. Macromol Biosci. 2011;11(6):748–764. doi:10.1002/mabi.201000388
   PubMed Web of Science ®Google Scholar
• Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134(2):577–594. doi:10.1053/j.gastro.2007.11.059
   PubMed Web of Science ®Google Scholar
• Alam MT, Amos GCA, Murphy ARJ, et al. Microbial imbalance in inflammatory bowel disease patients at different taxonomic levels. Gut Pathog. 2020;12(1):1. doi:10.1186/s13099-019-0341-6
   PubMed Web of Science ®Google Scholar
• Musch MW, Wang Y, Claud EC, et al. Lubiprostone decreases mouse colonic inner mucus layer thickness and alters intestinal microbiota. Dig Dis Sci. 2013;58(3):668–677. doi:10.1007/s10620-012-2509-5
   PubMed Web of Science ®Google Scholar
• Johnstone RW, Ruefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci. 2000;25(1):1–6. doi:10.1016/S0968-0004(99)01493-0
   PubMed Web of Science ®Google Scholar
• Chan LMS, Lowes S, Hirst BH. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci. 2004;21(1):25–51. doi:10.1016/j.ejps.2003.07.003
   PubMed Web of Science ®Google Scholar
• Gavhane YN, Yadav AV. Loss of orally administered drugs in GI tract. Saudi Pharm J. 2012;20(4):331–344. doi:10.1016/j.jsps.2012.03.005
   PubMed Web of Science ®Google Scholar
• Takano M, Yumoto R, Murakami T. Expression and function of efflux drug transporters in the intestine. Pharmacol Ther. 2006;109(1–2):137–161. doi:10.1016/j.pharmthera.2005.06.005
   PubMed Web of Science ®Google Scholar
• Liu J, Li M, Luo Z, et al. Design of nanocarriers based on complex biological barriers in vivo for tumor therapy. Nano Today. 2017;15:56–90. doi:10.1016/j.nantod.2017.06.010
   Web of Science ®Google Scholar
• Klotz U, Schwab M. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Adv Drug Del Rev. 2005;57(2):267–279. doi:10.1016/j.addr.2004.08.007
   PubMed Web of Science ®Google Scholar
• Frei P, Biedermann L, Manser CN, et al. Topical therapies in inflammatory bowel disease. Digestion. 2012;86(s1):36–44. doi:10.1159/000341947
   PubMedGoogle Scholar
• Mariangela A, Gionata F, Daniela G, et al. Biologic therapies in ulcerative colitis: primi inter pares? Curr Drug Targets. 2018;19(7):748–756. doi:10.2174/1389450117666160527142719
   PubMed Web of Science ®Google Scholar
• Fiorino G, Fazio M, Danese S. Biosimilar therapies in inflammatory bowel disease: should we care about patient profile? Expert Rev Clin Immunol. 2016;12(4):361–363. doi:10.1586/1744666X.2016.1141050
   PubMed Web of Science ®Google Scholar
• Iqbal S, Du X, Wang J, et al. Surface charge tunable nanoparticles for TNF-α siRNA oral delivery for treating ulcerative colitis. Nano Res. 2018;11(5):2872–2884. doi:10.1007/s12274-017-1918-3
   Web of Science ®Google Scholar
• Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov. 2003;2(4):289–295. doi:10.1038/nrd1067
   PubMed Web of Science ®Google Scholar
• Anselmo AC, Gokarn Y, Mitragotri S. Non-invasive delivery strategies for biologics. Nat Rev Drug Discov. 2019;18(1):19–40. doi:10.1038/nrd.2018.183
   PubMed Web of Science ®Google Scholar
• Chung SW, Hil-lal TA, Byun Y. Strategies for non-invasive delivery of biologics. J Drug Target. 2012;20(6):481–501. doi:10.3109/1061186X.2012.693499
   PubMed Web of Science ®Google Scholar
• Ram PD, Vishwa VG, Beena GS, et al. Passive and active drug targeting: role of nanocarriers in rational design of anticancer formulations. Curr Pharm Des. 2019;25(28):3034–3056. doi:10.2174/1381612825666190830155319
   PubMed Web of Science ®Google Scholar
• Alavi M, Hamidi M. Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles. Drug Metab Pers Ther. 2019;34(1). doi:10.1515/dmpt-2018-0032
   PubMedGoogle Scholar
• Zhang X, Wu W. Ligand-mediated active targeting for enhanced oral absorption. Drug Discov Today. 2014;19(7):898–904. doi:10.1016/j.drudis.2014.03.001
   PubMed Web of Science ®Google Scholar
• Yun Y, Cho YW, Park K. Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery. Adv Drug Del Rev. 2013;65(6):822–832. doi:10.1016/j.addr.2012.10.007
   PubMed Web of Science ®Google Scholar
• Herrero EP, Alonso MJ, Csaba N. Polymer-based oral peptide nanomedicines. Ther Deliv. 2012;3(5):657–668. doi:10.4155/tde.12.40
   PubMedGoogle Scholar
• Lu L, Chen G, Qiu Y, et al. Nanoparticle-based oral delivery systems for colon targeting: principles and design strategies. Sci Bull. 2016;61:670–681.
   Web of Science ®Google Scholar
• Schmidt C, Lautenschlaeger C, Collnot E-M, et al. Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa—a first in vivo study in human patients. J Control Release. 2013;165:139–145.
   PubMed Web of Science ®Google Scholar
• Abdelmegid AM, Abdo FK, Ahmed FE, et al. Therapeutic effect of gold nanoparticles on DSS-induced ulcerative colitis in mice with reference to interleukin-17 expression. Sci Rep. 2019;9:10176.
   PubMed Web of Science ®Google Scholar
• Kim JJ, Bridle BW, Ghia J-E, et al. Targeted inhibition of serotonin type 7 (5-HT7) receptor function modulates immune responses and reduces the severity of intestinal inflammation. J Immunol. 2013;190:4795.
   PubMed Web of Science ®Google Scholar
• Tirosh B, Khatib N, Barenholz Y, et al. Transferrin as a luminal target for negatively charged liposomes in the inflamed colonic mucosa. Mol Pharm. 2009;6:1083–1091.
   PubMed Web of Science ®Google Scholar
• Peterson CGB, Eklund E, Taha Y, et al. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am J Gastroenterol. 2002;97:1755–1762.
   PubMed Web of Science ®Google Scholar
• Canny G, Levy O, Furuta GT, et al. Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci U S A. 2002;99:3902–3907.
   PubMed Web of Science ®Google Scholar
• Courthion H, Mugnier T, Rousseaux C, et al. Self-assembling polymeric nanocarriers to target inflammatory lesions in ulcerative colitis. J Control Release. 2018;275:32–39.
   PubMed Web of Science ®Google Scholar
• Lee Y, Sugihara K, Gillilland MG, et al. Hyaluronic acid–bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis. Nat Mater. 2020;19:118–126.
   PubMed Web of Science ®Google Scholar
• Li W, Li Y, Liu Z, et al. Hierarchical structured and programmed vehicles deliver drugs locally to inflamed sites of intestine. Biomaterials. 2018;185:322–332.
   PubMed Web of Science ®Google Scholar
• Zhao J, Gao W, Cai X, et al. Nanozyme-mediated catalytic nanotherapy for inflammatory bowel disease. Theranostics. 2019;9:2843–2855.
   PubMed Web of Science ®Google Scholar
• Zhang S, Cho WJ, Jin AT, et al. Heparin-coated albumin nanoparticles for drug combination in targeting inflamed intestine. Adv Healthcare Mater. 2020;9:2000536.
   Web of Science ®Google Scholar
• Zhang L, Gui S, Xu Y, et al. Colon tissue-accumulating mesoporous carbon nanoparticles loaded with Musca domestica cecropin for ulcerative colitis therapy. Theranostics. 2021;11:3417–3438.
   PubMed Web of Science ®Google Scholar
• Zhao S, Li Y, Liu Q, et al. An orally administered CeO2@montmorillonite nanozyme targets inflammation for inflammatory bowel disease therapy. Adv Funct Mater. 2020;30:2004692.
   Web of Science ®Google Scholar
• Chung CH, Jung W, Keum H, et al. Nanoparticles derived from the natural antioxidant rosmarinic acid ameliorate acute inflammatory bowel disease. ACS Nano. 2020;14:6887–6896.
   PubMed Web of Science ®Google Scholar
• Lee Y, Lee S, Jon S. Biotinylated bilirubin nanoparticles as a tumor microenvironment-responsive drug delivery system for targeted cancer therapy. Adv Sci. 2018;5:1800017.
   Web of Science ®Google Scholar
• Lee S, Lee Y, Kim H, et al. Bilirubin nanoparticle-assisted delivery of a small molecule-drug conjugate for targeted cancer therapy. Biomacromolecules. 2018;19:2270–2277.
   PubMed Web of Science ®Google Scholar
• Xiao B, Merlin D. Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease. Expert Opin Drug Deliv. 2012;9:1393–1407.
   PubMed Web of Science ®Google Scholar
• Dreaden EC, Morton SW, Shopsowitz KE, et al. Bimodal tumor-targeting from microenvironment responsive hyaluronan layer-by-layer (LbL) nanoparticles. ACS Nano. 2014;8:8374–8382.
   PubMed Web of Science ®Google Scholar
• Rios de la Rosa JM, Tirella A, Gennari A, et al. The CD44-mediated uptake of hyaluronic acid-based carriers in macrophages. Adv Healthcare Mater. 2017;6:1601012.
   Web of Science ®Google Scholar
• Na YR, Stakenborg M, Seok SH, et al. Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD. Nat Rev Gastroenterol Hepatol. 2019;16:531–543.
   PubMed Web of Science ®Google Scholar
• Tlaxca JL, Rychak JJ, Ernst PB, et al. Ultrasound-based molecular imaging and specific gene delivery to mesenteric vasculature by endothelial adhesion molecule targeted microbubbles in a mouse model of Crohn’s disease. J Control Release. 2013;165:216–225.
   PubMed Web of Science ®Google Scholar
• Bachmann C, Klibanov AL, Olson TS, et al. Targeting Mucosal Addressin Cellular Adhesion Molecule (MAdCAM)-1 to noninvasively image experimental Crohn’s disease. Gastroenterology. 2006;130:8–16.
   PubMed Web of Science ®Google Scholar
• Zhang M, Yang C, Merlin D. P084 oral delivery of nanoparticles loaded with ginger active compound, 6-shogaol, attenuates ulcerative colitis and promotes wound healing in a murine model of ulcerative colitis. Gastroenterology. 2018;154:S44.
   Web of Science ®Google Scholar
• Zhang M, Xu C, Wen L, et al. A hyaluronidase-responsive nanoparticle-based drug delivery system for targeting colon cancer cells. Cancer Res. 2016;76:7208.
   PubMed Web of Science ®Google Scholar
• Xiao B, Zhang Z, Viennois E, et al. Combination therapy for ulcerative colitis: orally targeted nanoparticles prevent mucosal damage and relieve inflammation. Theranostics. 2016;6:2250–2266.
   PubMed Web of Science ®Google Scholar
• Xiao B, Xu Z, Viennois E, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther. 2017;25:1628–1640.
   PubMed Web of Science ®Google Scholar
• Gou S, Huang Y, Wan Y, et al. Multi-bioresponsive silk fibroin-based nanoparticles with on-demand cytoplasmic drug release capacity for CD44-targeted alleviation of ulcerative colitis. Biomaterials. 2019;212:39–54.
   PubMed Web of Science ®Google Scholar
• Schippers A, Muschaweck M, Clahsen T, et al. β7-Integrin exacerbates experimental DSS-induced colitis in mice by directing inflammatory monocytes into the colon. Mucosal Immunol. 2016;9:527–538.
   PubMed Web of Science ®Google Scholar
• Truffi M, Colombo M, Peñaranda-Avila J, et al. Nano-targeting of mucosal addressin cell adhesion molecule-1 identifies bowel inflammation foci in murine model. Nanomedicine. 2017;12:1547–1560.
   PubMed Web of Science ®Google Scholar
• Ooi VE, Liu F. Immunomodulation and anti-cancer activity of polysaccharide-protein complexes. Curr Med Chem. 2000;7:715–729.
   PubMed Web of Science ®Google Scholar
• Chan GC-F, Chan WK, Sze DM-Y. The effects of β-glucan on human immune and cancer cells. J Hematol Oncol. 2009;2:25.
   PubMed Web of Science ®Google Scholar
• Sun Y, Duan B, Chen H, et al. A novel strategy for treating inflammatory bowel disease by targeting delivery of methotrexate through glucan particles. Adv Healthcare Mater. 2020;9:1901805.
   Web of Science ®Google Scholar
• Wileman TE, Lennartz MR, Stahl PD. Identification of the macrophage mannose receptor as a 175-kDa membrane protein. Proc Natl Acad Sci U S A. 1986;83:2501.
   PubMed Web of Science ®Google Scholar
• Chu S, Tang C, Yin C. Effects of mannose density on in vitro and in vivo cellular uptake and RNAi efficiency of polymeric nanoparticles. Biomaterials. 2015;52:229–239.
   PubMed Web of Science ®Google Scholar
• Sun Q, Arif M, Chi Z, et al. Macrophages-targeting mannosylated nanoparticles based on inulin for the treatment of inflammatory bowel disease (IBD). Int J Biol Macromol. 2021;169:206–215.
   PubMed Web of Science ®Google Scholar
• Lautenschläger C, Schmidt C, Fischer D, et al. Drug delivery strategies in the therapy of inflammatory bowel disease. Adv Drug Del Rev. 2014;71:58–76.
   PubMed Web of Science ®Google Scholar
• Li W, Liu D, Zhang H, et al. Microfluidic assembly of a nano-in-micro dual drug delivery platform composed of halloysite nanotubes and a pH-responsive polymer for colon cancer therapy. Acta Biomater. 2017;48:238–246.
   PubMed Web of Science ®Google Scholar
• Liu D, Zhang H, Cito S, et al. Core/shell nanocomposites produced by superfast sequential microfluidic nanoprecipitation. Nano Lett. 2017;17:606–614.
   PubMed Web of Science ®Google Scholar
• Oshi MA, Lee J, Naeem M, et al. Curcumin nanocrystal/pH-responsive polyelectrolyte multilayer core-shell nanoparticles for inflammation-targeted alleviation of ulcerative colitis. Biomacromolecules. 2020;9:3571–3581.
   Google Scholar
• Oshi MA, Naeem M, Bae J, et al. Colon-targeted dexamethasone microcrystals with pH-sensitive chitosan/alginate/Eudragit S multilayers for the treatment of inflammatory bowel disease. Carbohydr Polym. 2018;198:434–442.
   PubMed Web of Science ®Google Scholar
• Friesen DT, Shanker R, Crew M, et al. Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview. Mol Pharm. 2008;5:1003–1019.
   PubMed Web of Science ®Google Scholar
• Bertoni S, Liu Z, Correia A, et al. pH and reactive oxygen species-sequential responsive nano-in-micro composite for targeted therapy of inflammatory bowel disease. Adv Funct Mater. 2018;28:1806175.
   Web of Science ®Google Scholar
• Deshpande S, Sharma S, Koul V, et al. Core–shell nanoparticles as an efficient, sustained, and triggered drug-delivery system. ACS Omega. 2017;2:6455–6463.
   PubMed Web of Science ®Google Scholar
• Naeem M, Bae J, Oshi MA, et al. Colon-targeted delivery of cyclosporine A using dual-functional Eudragit(®) FS30D/PLGA nanoparticles ameliorates murine experimental colitis. Int J Nanomedicine. 2018;13:1225–1240.
   PubMed Web of Science ®Google Scholar
• Chen L, You Q, Hu L, et al. The antioxidant procyanidin reduces reactive oxygen species signaling in macrophages and ameliorates experimental colitis in mice. Front Immunol. 2018;8:1910.
   PubMed Web of Science ®Google Scholar
• Dagli Ü, Balk M, Yücel D, et al. The role of reactive oxygen metabolites in ulcerative colitis. Inflamm Bowel Dis. 1997;3:260–264.
   PubMed Web of Science ®Google Scholar
• Lee SH, Gupta MK, Bang JB, et al. Current progress in reactive oxygen species (ROS)‐responsive materials for biomedical applications. Adv Healthcare Mater. 2013;2(6):908–915. doi:10.1002/adhm.201200423
   Web of Science ®Google Scholar
• Li S, Xie A, Li H, et al. A self-assembled, ROS-responsive janus-prodrug for targeted therapy of inflammatory bowel disease. J Control Release. 2019;316:66–78. doi:10.1016/j.jconrel.2019.10.054
   PubMed Web of Science ®Google Scholar
• Tapeinos C, Pandit A. Physical, chemical, and biological structures based on ROS-sensitive moieties that are able to respond to oxidative microenvironments. Adv Mater. 2016;28(27):5553–5585. doi:10.1002/adma.201505376
   PubMed Web of Science ®Google Scholar
• Saravanakumar G, Kim J, Kim WJ. Reactive-oxygen-species-responsive drug delivery systems: promises and challenges. Adv Sci. 2017;4(1):1600124. doi:10.1002/advs.201600124
   Web of Science ®Google Scholar
• Zhang Q, Zhang F, Chen Y, et al. Structure–property correlations of reactive oxygen species-responsive and hydrogen peroxide-eliminating materials with anti-oxidant and anti-inflammatory activities. Chem Mater. 2017;29(19):8221–8238. doi:10.1021/acs.chemmater.7b02412
   Web of Science ®Google Scholar
• Zhang D, Wei Y, Chen K, et al. Biocompatible reactive oxygen species (ROS)-responsive nanoparticles as superior drug delivery vehicles. Adv Healthcare Mater. 2015;4(1):69–76. doi:10.1002/adhm.201400299
   Web of Science ®Google Scholar
• Li C, Zhao Y, Cheng J, et al. A proresolving peptide nanotherapy for site-specific treatment of inflammatory bowel disease by regulating proinflammatory microenvironment and gut microbiota. Adv Sci. 2019;6(18):1900610. doi:10.1002/advs.201900610
   Web of Science ®Google Scholar
• Zhang Q, Zhang F, Li S, et al. A multifunctional nanotherapy for targeted treatment of colon cancer by simultaneously regulating tumor microenvironment. Theranostics. 2019;9(13):3732–3753. doi:10.7150/thno.34377
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867. doi:10.1038/nature01322
   PubMed Web of Science ®Google Scholar
• Zhang Q, Tao H, Lin Y, et al. A superoxide dismutase/catalase mimetic nanomedicine for targeted therapy of inflammatory bowel disease. Biomaterials. 2016;105:206–221. doi:10.1016/j.biomaterials.2016.08.010
   PubMed Web of Science ®Google Scholar
• Patlevič P, Vašková J, Švorc P, et al. Reactive oxygen species and antioxidant defense in human gastrointestinal diseases. Integr Med Res. 2016;5(4):250–258. doi:10.1016/j.imr.2016.07.004
   PubMed Web of Science ®Google Scholar
• Kim T-I, Rothmund T, Kissel T, et al. Bioreducible polymers with cell penetrating and endosome buffering functionality for gene delivery systems. J Control Release. 2011;152(1):110–119. doi:10.1016/j.jconrel.2011.02.013
   PubMed Web of Science ®Google Scholar
• Wei X, Liao J, Davoudi Z, et al. Folate receptor-targeted and GSH-responsive carboxymethyl chitosan nanoparticles containing covalently entrapped 6-mercaptopurine for enhanced intracellular drug delivery in leukemia. Mar Drugs. 2018;16(11):439. doi:10.3390/md16110439
   PubMed Web of Science ®Google Scholar
• Gou S, Chen Q, Liu Y, et al. Green fabrication of ovalbumin nanoparticles as natural polyphenol carriers for ulcerative colitis therapy. ACS Sustain Chem Eng. 2018;6(10):12658–12667. doi:10.1021/acssuschemeng.8b01613
   Web of Science ®Google Scholar
• Zhang S, Langer R, Traverso G. Nanoparticulate drug delivery systems targeting inflammation for treatment of inflammatory bowel disease. Nano Today. 2017;16:82–96. doi:10.1016/j.nantod.2017.08.006
   PubMed Web of Science ®Google Scholar
• Cheng S, Shen H, Zhao S, et al. Orally administered mesoporous silica capped with the cucurbit[8]uril complex to combat colitis and improve intestinal homeostasis by targeting the gut microbiota. Nanoscale. 2020;12(28):15348–15363. doi:10.1039/D0NR03037F
   PubMed Web of Science ®Google Scholar
• Chhour P, Naha PC, O’Neill SM, et al. Labeling monocytes with gold nanoparticles to track their recruitment in atherosclerosis with computed tomography. Biomaterials. 2016;87:93–103. doi:10.1016/j.biomaterials.2016.02.009
   PubMed Web of Science ®Google Scholar
• Mohajeri M, Iranpour P, Vahidi Y, et al. Pegylated deoxycholic acid coated gold nanoparticles as a highly stable CT contrast agent. ChemistrySelect. 2020;5(29):9119–9126. doi:10.1002/slct.202001634
   Web of Science ®Google Scholar
• Liu X, Zhang M, Yan D, et al. A smart theranostic agent based on Fe-HPPy@Au/DOX for CT imaging and PTT/chemotherapy/CDT combined anticancer therapy. Biomater Sci. 2020;8(15):4067–4072. doi:10.1039/D0BM00623H
   PubMed Web of Science ®Google Scholar
• Su Y, Liu S, Guan Y, et al. Renal clearable hafnium-doped carbon dots for CT/fluorescence imaging of orthotopic liver cancer. Biomaterials. 2020;255:120110. doi:10.1016/j.biomaterials.2020.120110
   PubMed Web of Science ®Google Scholar
• Truffi M, Sevieri M, Morelli L, et al. Anti-MAdCAM-1-conjugated nanocarriers delivering quantum dots enable specific imaging of inflammatory bowel disease. Int J Nanomedicine. 2020;15:8537–8552. doi:10.2147/IJN.S264513
   PubMed Web of Science ®Google Scholar
• Eliakim R, Magro F. Imaging techniques in IBD and their role in follow-up and surveillance. Nat Rev Gastroenterol Hepatol. 2014;11(12):722–736. doi:10.1038/nrgastro.2014.144
   PubMed Web of Science ®Google Scholar
• Winklhofer S, Lin W-C, Wang ZJ, et al. Comparison of positive oral contrast agents for abdominopelvic CT. Am J Roentgenol. 2019;212(5):1037–1043. doi:10.2214/AJR.18.20445
   PubMed Web of Science ®Google Scholar
• Smith-Bindman R, Lipson J, Marcus R, et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med. 2009;169(22):2078–2086. doi:10.1001/archinternmed.2009.427
   PubMedGoogle Scholar
• Naha PC, Hsu JC, Kim J, et al. Dextran-coated cerium oxide nanoparticles: a computed tomography contrast agent for imaging the gastrointestinal tract and inflammatory bowel disease. ACS Nano. 2020;14(8):10187–10197. doi:10.1021/acsnano.0c03457
   PubMed Web of Science ®Google Scholar
• Naha PC, Liu Y, Hwang G, et al. Dextran-coated iron oxide nanoparticles as biomimetic catalysts for localized and pH-activated biofilm disruption. ACS Nano. 2019;13(5):4960–4971. doi:10.1021/acsnano.8b08702
   PubMed Web of Science ®Google Scholar
• Hu G, Guo M, Xu J, et al. Nanoparticles targeting macrophages as potential clinical therapeutic agents against cancer and inflammation. Front Immunol. 2019;10:1998. doi:10.3389/fimmu.2019.01998
   PubMed Web of Science ®Google Scholar
• Baldim V, Bedioui F, Mignet N, et al. The enzyme-like catalytic activity of cerium oxide nanoparticles and its dependency on Ce3+ surface area concentration. Nanoscale. 2018;10(15):6971–6980. doi:10.1039/C8NR00325D
   PubMed Web of Science ®Google Scholar
• Shi X, Yan Y, Wang P, et al. In vitro and in vivo study of pH-sensitive and colon-targeting P(LE-IA-MEG) hydrogel microspheres used for ulcerative colitis therapy. Eur JPharm Biopharm. 2018;122:70–77. doi:10.1016/j.ejpb.2017.10.003
   PubMed Web of Science ®Google Scholar
• Pujara N, Wong KY, Qu Z, et al. Oral delivery of β-lactoglobulin-nanosphere-encapsulated resveratrol alleviates inflammation in winnie mice with spontaneous ulcerative colitis. Mol Pharm. 2020;18(2):627–640. doi:10.1021/acs.molpharmaceut.0c00048
   PubMedGoogle Scholar
• Wang X, Yan -J-J, Wang L, et al. Rational design of polyphenol-poloxamer nanovesicles for targeting inflammatory bowel disease therapy. Chem Mater. 2018;30(12):4073–4080. doi:10.1021/acs.chemmater.8b01173
   Web of Science ®Google Scholar